- Home
- RPTX vs LPTX Comparison
RPTX vs LPTX Comparison
Compare RPTX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- LPTX
- Stock Information
- Founded
- RPTX 2016
- LPTX 2011
- Country
- RPTX Canada
- LPTX United States
- Employees
- RPTX N/A
- LPTX N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RPTX Health Care
- LPTX Health Care
- Exchange
- RPTX Nasdaq
- LPTX Nasdaq
- Market Cap
- RPTX 155.4M
- LPTX 143.1M
- IPO Year
- RPTX 2020
- LPTX N/A
- Fundamental
- Price
- RPTX $3.59
- LPTX $3.24
- Analyst Decision
- RPTX Strong Buy
- LPTX Strong Buy
- Analyst Count
- RPTX 1
- LPTX 5
- Target Price
- RPTX $10.00
- LPTX $10.40
- AVG Volume (30 Days)
- RPTX 71.8K
- LPTX 483.3K
- Earning Date
- RPTX 11-07-2024
- LPTX 11-19-2024
- Dividend Yield
- RPTX N/A
- LPTX N/A
- EPS Growth
- RPTX N/A
- LPTX N/A
- EPS
- RPTX N/A
- LPTX N/A
- Revenue
- RPTX $68,683,000.00
- LPTX N/A
- Revenue This Year
- RPTX $16.85
- LPTX N/A
- Revenue Next Year
- RPTX N/A
- LPTX N/A
- P/E Ratio
- RPTX N/A
- LPTX N/A
- Revenue Growth
- RPTX N/A
- LPTX N/A
- 52 Week Low
- RPTX $2.71
- LPTX $1.32
- 52 Week High
- RPTX $8.49
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- RPTX 53.00
- LPTX 49.67
- Support Level
- RPTX $3.37
- LPTX $3.40
- Resistance Level
- RPTX $4.05
- LPTX $3.92
- Average True Range (ATR)
- RPTX 0.26
- LPTX 0.47
- MACD
- RPTX 0.00
- LPTX -0.04
- Stochastic Oscillator
- RPTX 40.65
- LPTX 22.11
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .